Prelude Therapeutics Incorporated (PRLD) Institutional Ownership

Based on Q1 2026 13F filings, institutional ownership of Prelude Therapeutics Incorporated stands at 29.3%, held across 55 reporting institutions.

ORBIMED ADVISORS LLC is the largest reported institutional holder of PRLD, with approximately 10,909,256 shares worth $0.04B as of Q1 2026.

Yes — 6 widely-followed marquee investors appear among the top 25 institutional holders of PRLD, including TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC.

Our composite Smart Money Score for PRLD is 82 out of 100 (Strong Smart Money). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

15 institutions opened new positions in PRLD during Q1 2026, while 7 fully exited. 36 added to existing positions and 4 trimmed.

PRLD institutional ownership rose by 6.96 percentage points quarter-over-quarter, with a net change of +8 holders.

The top 10 institutions account for 90.4% of all reported 13F value in PRLD, and the top 25 account for 98.8%.

All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.